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Introduction
It is well recognized that controlled-release dosage forms
may offer several advantages over immediate release
formulations of the same drug. The most common controll-
ed delivery system containing uniformly dissolved or
dispersed drug are tablets and particles because of its ef-
fectiveness as well as low cost and ease of manufacturing.[1]
Nevertheless, their release behaviour is intrinsically non-
linear in nature, with continuously diminishing release
rate.[2,3] This is a direct result from a decreasing release rate
with time due to an increase in diffusion resistance and/or a
decrease in effective area at the diffusion front.[4] With the
emergent need for optimization of therapy, systems provid-
ing programmable rates of release other than the typical
first-order are becoming more imperative.[5] For this reason,
constant-rate delivery has always been one of the main tar-
gets of controlled-release systems, especially for drugs with
a narrow therapeutic index.[5] Over the last years, consider-
able efforts have been spent in the development of new
Summary:Theaimofthisstudywastodesignnewsoyprotein-
based bi-layered co-injection moulded matrix systems aimed
to achieve controlled drug delivery. The devices consisted of a
drug-free outer layer (skin) and a drug-containing core. The
systems overcame the inherent disadvantage of non-linear
releaseassociatedwithdiffusion-controlledsingle-layermatrix
devices by providing additional releasing area with time to
compensate for the decreasing release rate. Asexpected, the bi-
layer devices presented a significant decrease in drug release
rate when compared with a correspondent single layer matrix
system. The skin thickness and the degree of crosslinking of
the core appeared to be very important tools to tailor the
release patterns. Furthermore, due to the amphoteric nature of
the soy protein, the developed devices evidenced a pH-
dependent behaviour. The mechanisms of drug release were
also elucidated at two different pH values: i) pH 5.0, near
the isoelectric point of soy (low matrix solubility); and ii) pH
7.4, physiological pH (high matrix solubility). Consequently,
changing the release medium from pH 5.0 to pH 7.4 after two
hours, led to an abrupt increase in drug release and the devices
presented a typical controlled drug delivery profile: slow
release/fast release.Theseevidencesmayprovide for thedevel-
opment of individual systems with different release onsets that
in combination may exhibit drug releases at predetermined
times in a pre-programmed way. Another possibility is the
production of three-layer devices presenting bimodal release
profiles (fast release/slow release/fast release) by similar
technologies.
Scanning electron micrograph of a developed bi-layer device.
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delivery concepts in order to achieve the desired controlled-
release. Examples included the use of geometry factors
(donut shape, core in cup, biconcave,. . .), erosion/dissolu-
tion control and swelling control mechanisms (multi-layer
tablets) and matrix-membrane combinations.[1,4,6–16] How-
ever, some of those systems are difficult or impractical to
manufacture, environmentally unfriendly and presenting
low versatility in terms of formulations.
In a previous study, soy-protein bi-layer cylindrical
devices of very small dimensions were produced using
an innovative technique in the field, a two-material co-
injection moulding.[17] This technique allowed, in one step,
the joining of two polymers into a moulded device that did
not require any further finishing operations.[17] The imme-
diate results were devices with a well-defined geometry and
skin/core morphology.[17] Soy protein was selected as the
matrix former due to its high availability,[18] good melt
processability,[19] high thermal stability[19] and non-cyto-
toxicity,[20] features that distinguish positively soy from
other protein-like materials already used in the pharma-
ceutical field.[21–27] Therefore, the second goal to be reach-
ed is to investigate the suitability of the developed bi-layer
devices to attain controlled-delivery behaviour. Conse-
quently, the main targets of this study were: i) compare the
release patterns of the previously investigated single layer
devices with those from the newly developed bi-layer ones;
ii) to investigate parameters such as crosslinking degree,
skin/core ratios and pH of the immersion solution affecting
the drug delivery profiles; and iii) validate the suitability of




The following materials were used as received from the
manufacturers: soy protein isolate (amorphous, 83.4 wt.-%
protein on dry basis, Loders Crocklaan BV, Wormeveer, The
Netherlands), glycerol, glyoxal (40 vol.-%), o-phthaldialde-
hyde (OPA) and anhydrous theophylline (TH, C7H8N4O2,
purity >98%, Figure 1) (from Sigma-Aldrich Chemie BV,
Zwijndrecht, The Netherlands).
Hydroxylapatite (a non-sintered bone like ceramic filler
with an average particle size <20 mm) was supplied by CAM
Implants BV, Leiden, The Netherlands. All the other reagents
used in the experiments were of analytical grades.
Glyoxal was the selected crosslinker due to its dialdehyde
functionality able to react with the free e-amine groups of the
lysine (or hydroxylysine) residues of soy, (Equation (1):
Moreover, glyoxal has been shown to be less toxic for human
cells than the most commonly used formaldehyde and glu-
taraldehyde crosslinkers.[28]
Premix Preparation
Premixes of the matrix material (soy protein isolate), filler and
drug were prepared prior to processing. The constituents of
each formulation were weighed and transferred into a mixer
container. This was followed by mixing all the compounds for
15 min at room temperature (25 8C) using a Bear Varimixer
(Bear, Denmark) equipped with a low shear spiral-mixing tool
at a speed of 45 rpm.
Melt-Extrusion
The solid premixes were converted into plastic materials, with
encapsulated TH, by extrusion.[29–32] They were directly fed
into a co-rotating twin-screw extruder (Berstorff, Hannover,
Germany, D¼ 25 mm and L¼ 40D). The liquids, such as plas-
ticizers (glycerol and water (or a buffer solution of acetic acid
(CH3COOH)/sodium acetate (CH3COONa) 200 103 M,
pH 4)) and crosslinker (glyoxal), were concurrently injected
into the second feeding zone of the extruder barrel with a piston
pump (Pro Minet, Verder BV, The Netherlands). Table 1
Figure 1. Chemical structure of theophylline (TH, C7H8N4O2).
Table 1. Composition of the investigated matrices (all quantities







Soy 100 100 100 100
Glycerol 10 10 10 10
Water 30 30 30 30
Glyoxal – – 0.6 –
Theophylline – 20 20 –
Hydroxylapatite – – – 30
pH 7.0 7.0 7.0 7.0
Free amine group
content (%)
– 97.6 0.5 55.9 1.0 –
a) SItp: thermoplastic soy matrix.
b) SIDtp: thermoplastic soy matrix with encapsulated theophylline.
c) 0.6X-SIDtp: glyoxal crosslinked thermoplastic soy matrix with
encapsulated theophylline.
d) SI-HADtp: hydroxylapatite reinforced thermoplastic soy matrix
with encapsulated theophylline.
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presents all the formulations prepared during this experiment
and the respective codes.
The extrusion conditions were based on preliminary
research work.[29–32]
Sample Preparation
Axi-symmetrical dumbbell-like skin/core specimens of
1.5 mm in diameter (SIs/SIDc, SIDs/0.6X-SIDc, SI-HAs/SIDc
and SI-HAs/0.6X-SIDc, where s and c refers to the skin and
core, respectively) were co-injection moulded in a 2 material
Ferromatik-Milacron K85 machine. The machine was oper-
ated in mono-sandwich mode.[17] The processing conditions
used for the production of all the mouldings were previously
optimised.[17]
Conventional injection moulding was also performed with
the SIDtp and 0.6X-SIDtp for comparison purpose.
Protein Solubility
A 0.1 wt.-% protein solution was prepared by dispersing about
50 mg of protein powders in 45 g of demineralized water. The
dispersion was magnetically stirred until complete dispersion
of the powder (approximately 30 minutes). The pH values of
the solutions were adjusted to the desired pH values (in the
case, pH values of 3, 4, 5, 6, 7 and 9) using 0.1 M HCl or 0.1 M
NaOH. The solutions were again stirred during 1 hour and the
pH values verified and adjusted if necessary. When the pH
values were stable, the total weight was brought to 50 g with
additional water. Subsequently, the dispersions were centri-
fuged for 10 min at 13 500 rpm. The protein content in the
supernatant was determined by Kjeldahl analysis as explained
in section 2.7. However, the digestion conditions were different
for these liquid samples and composed of three steps: i) 160 8C
during 1 h; ii) 260 8C during another 1 h; and iii) 420 8C during
another 50 minutes. The protein solubility at the different pH
values was calculated according to:
Solubility ð%Þ ¼ ðNsup=NtotÞ  100 ð2Þ
The protein content of the supernatant (Nsup) was calculated
by Equation (3):
Nsup ð%Þ ¼ f½ðVHCl  0:1  14  6:25Þ=Wd  1000g  100
ð3Þ
Wd is the weight of the supernatant tested. TheNtot corresponds
to the protein content of the dry samples used to prepare the
dispersions and is calculated by Equation (4):
Ntot ð%Þ ¼ ½ðVHCl  0:1  14  6:25Þ=WD  100 ð4Þ
Where, VHCl is the volume of 0.1 M HCl used during the
Kjeldahl titration, 14 is the atomic mass of nitrogen (N) and
6.25 the Kjeldahl factor of soy. WD is the dry weight of the
protein powder sample previously tested.
Crosslinking Degree
The crosslinking degree of the produced specimens was evalu-
ated through the quantification of the reduction of the res-
pective free amine-group content. This was determined
using the previously described OPA (o-phthaldialdehyde)
method.[29–31]
Morphology
The devices morphology was assessed before and after the
release tests by observation of the respective cross-sections
using a scanning electron microscope (Leica Cambridge S360,
Cambridge, UK). The specimens were first dried under
vacuum, afterwards cryogenically broken and finally gold
sputtered before observation.
Drug Release Studies
The release kinetics of the model drug TH from the bi-layer
devices was also assessed. Randomly selected batches of
specimens were immersed, at 37 8C, in isotonic saline solutions
(ISS, NaCl, 9 g  l1þ 1 wt.-% sodium azide (NaN3)) buffered
at two different pH values:
i) pH 5.0 0.03: 0.2 M acetic acid (CH3CO2H)/0.2 M sodium
acetate (CH3CO2Na) buffer; and ii) pH 7.4 0.02: 0.2 M
tris(hydroxymethyl)aminomethane/0.2 M hydrochloric acid
(HCl) buffer (0.2 M Tris-HCl buffer).
At preset times 1 ml of each solution was taken out and
replaced by 1 ml of fresh solution. The solution was then
carefully filtered using a Microcon filter (Amicon, The Nether-
lands) of 10 kD mesh. The supernatant was assayed for
released of TH at 273 nm using an Alliance HPLC-UV System
(Water Cromatography BV, The Netherlands) coupled with a
Waters 2690 Separations Module and a Waters 996 Photodiode
Array Detector. The selected mobile phase corresponded to a
mixture of water/acetonitrile (80:20 vol.-%) used at a flow rate
of 0.75 ml min1. A Chrompack Varian Hypersyl 5 mm ODS
column of 150 4.6 mm was used in combination with a 1 cm
pre-column. All experiments were conducted in triplicate.
Statistics
Result data were expressed as mean standard error of the
mean. An unpaired t test (Student’s t test) was performed,
considering a P< 0.05 as statistically significant.
Results and Discussion
Controlled Release from Bi-Layer Devices
The aim of this study was two achieve a controlled release
from bi-layer matrices, exhibiting first a slow release and
then a fast release. The investigated drug containing SIDtp
and 0.6X-SIDtp matrices were used as the drug-containing
inner layers to provide both slow release (in acidic
surroundings) and fast release (in neutral surroundings).[33]
In order to further hinder drug diffusion out of the device, a
soy protein-based drug-free outer layer was used. The cross-
sections of the bi-layer devices can be seen in Figure 2.
In general, the systems presented a good skin/core adhe-
sion and well-defined skin/core geometry. The differences
Controlled Delivery Achieved with Bi-Layer Matrix Devices Produced by Co-Injection Moulding 797
Macromol. Biosci. 2004, 4, 795–801 www.mbs-journal.de  2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
in skin thicknesses are also evident. The skin/core ratios of
the devices with the crosslinked cores (SIs/0.6X-SIc and SI-
HAs/0.6X-SIDc) (Figures 2B and D) were higher than those
of the devices with non-crosslinked core (SIs/SIDc and SI-
HAs/SIDc) (Figures 2A and C). The reason for these
differences can be found elsewhere.[17]
As can be observed in Figure 3, the addition of the drug-
free outer layer (SItp) to the inner layers (SIDtp and 0.6X-
SIDtp) by co-injection moulding resulted in a significant
decrease of the release rates in both media (ISSþ acetate
buffer pH 5.0 and ISSþTris/HCl buffer pH 7.4).
The initial burst releases observed for the matrix systems
SIDtp and 0.6X-SIDtp could now be efficiently controlled.
Furthermore, the bi-layer device with the crosslinked core
(SIs/0.6X-SIDc) proved to be even more efficient than the bi-
layer device SIs/SIDc on decreasing the total release rates.
This fact must relate with: i) difference in core’s cross-
linking density and respective solubility as a function of
Figure 2. Scanning electron micrographs of the developed bi-layer devices: A1) SIs/SIDc-
general view; A2) SIs/SIDc-detail of the skin/core interface; B1) SIs/0.6X-SIDc-general
view; B2) SIs/0.6X-SIDc-detail of the skin/core interface; C1) SI-HAs/SIDc-general view;
C2) SI-HAs/SIDc-detail of the skin/core region; and D1) SI-HAs/0.6X-SIDc-general view;
D2) SI-HAs/0.6X-SIDc-detail of the skin/core region.
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pH (Figure 4);[33] and ii) difference in skin’s thickness
(Figure 2). In fact, the skin/core ratio of the system SIs/
0.6X-SIDc is higher than that of SIs/SIDc, assuming the
respective values of 0.33 0.07 and 0.11 0.04.
Nevertheless, all the release studies discussed above were
conducted either in ISSþ acetate buffer pH 5.0 or ISSþ
Tris/HCl buffer pH 7.4. However, to achieve a controlled
release system (slow release/fast release); it is of interest to
test the effect of a change in a release medium after a certain
period of time. In Figure 5 the cumulative amounts of TH
released from the matrix devices (SIDtp and 0.6X-SIDtp)
and the bi-layer devices (SIs/SIDc and SIs/0.6X-SIDc) in
ISSþ acetate buffer pH 5.0 and ISSþTris/HCl buffer pH
7.4 are displayed (medium change after 120 minutes).
As expected, the release rates significantly increased for
both systems after those 2 hours. Besides, it can be observed
that the presence of the drug-free skin layer in the
bi-material devices had the additional desired effect of in-
creasing the sharpness of the change in TH release rate,
specially the system SIs/0.6X-SIDc, and the systems presen-
ted the required controlled release behaviour (Figure 5).
In order to provide a faster initial release rate, the SI skin
material of the bi-layer devices was replaced by SI-HA. As
reported in a previous study,[33] the hydroxylapatite tends to
suffer a partial dissolution when in contact with the release
media, thus increasing the matrix porosity. Due to the
increased interfacial area, it is expected that when the drug
reaches this layers it would diffuse faster than it would in SI,
increasing as desired the release rate. However, from the
analysis of the Figure 6, it is possible to conclude that the
opposite effect occurred.
The main reason for this evidence relays on skin
thickness differences. The skin/core ratios of the bi-layer
systems SIHAs/SIDc and SIHAs/0.6X-SIDc (0.41 0.02
and 0.51 0.11, respectively) were considerably higher
than those for SIs/SIDc and SIs/0.6X-SIDc (0.11 0.04 and
0.33 0.07, respectively). The basis of this variation in
skin/core ratios is related with the different viscosities of the
studied materials.[17]
Besides, for both four systems the desired controlled
release (slow release/fast release) could be achieved, illus-
trating the efficiency of this new type of co-injection
moulded bi-layer devices.
Conclusions
A new type of polymer matrices providing controlled
release has been developed using an innovative technique in
the field: co-injection moulding. The major advantages of
these systems may include: i) easiness of production
(especially at industrial scale); ii) suitability for a large
variety of polymeric matrices; iii) applicability to different
types of drugs; iv) precise control of the skin/core ratio by
adjustment of the processing parameters; v) biodegrad-
ability; and vi) the possibility to achieve therapeutic blood
Figure 3. Effect of the addition by co-injection moulding of: A)
drug-free layer (SIs) on the release kinetics of theophylline from
SIDc (P< 0.05); and B) drug-free layer (SIs) on the release kinetics
of theophylline from 0.6X-SIDc (P< 0.05). Both tested in an
ISSþ acetate buffer pH 5.0 and in an ISSþTris/HCl buffer pH 7.4
(ISS, isotonic saline solution, 9 g/l NaClþ 1% sodium azide
(NaN3)).
Figure 4. Solubility profiles of the soy matrices SIDtp (^) and
0.6X-SIDtp (~) as a function of pH.
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levels similar to those obtained by administration of two
smaller doses over an extended period of time. Various para-
meters have been identified as potential tools to regulate the
time of drug release onset, such as crosslinking degree and
skin thickness. These evidences may provide for the devel-
opment of individual systems with different release onsets
(e.g. a system combining high crosslinking degree and high
skin thickness would present a more delayed release onset
than a non-crosslinked system with a thin skin layer). By
combining individual systems with different release onsets,
a therapeutic system may be developed exhibiting drug
releases at predetermined times in a pre-programmed way.
Another possibility is the production of three-layer devices
by technologies such as push–pull or co-injection mould-
ing/deep-coating. In these circumstances, if the third outer
layer is a drug containing fast disintegrating layer, it would
be eventually possible to produce new multi-layer devices
presenting bi-modal release profiles (fast release/slow
release/fast release).
However, in all cases, the in vivo performance of presen-
ted systems will always strongly depend on the variability
of the pH of the release site.
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